Consider This Before You Buy Biogen
Biogen (NASDAQ: BIIB) is the leading maker of medicine used to treat multiple sclerosis. However, new drugs from Roche Holdings (NASDAQOTH: RHHBY) and Celgene Corp. (NASDAQ: CELG) threaten its dominance and add pressure to the company to diversify itself.
In March, Roche Holdings earned an FDA green light to begin marketing Ocrevus, a new MS therapy approved for use both in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
